The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma
Open accessAbstract
Purpose: Germline mutations of the gene encoding subunit B of the mitochondrial enzyme succinate dehydrogenase (SDHB) predispose to malignant paraganglioma (PGL). Timely and accurate localization of these aggressive tumors is critical for guiding optimal treatment. Our aim is to evaluate the performance of functional imaging modalities in the detection of metastatic lesions of SDHB-associated PGL. Patients and Methods: Sensitivities for the detection of metastases were compared between [18 F]fluorodopamine ([18 F]FDA) and [18 F]fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET), iodine-123- (123 I) and iodine-131 (131 I) -metaiodobenzylguanidine (MIBG), 111 In-pentetreotide, and Tc-99m-methylene diphosphonate bone scintigraphy in 30 patients with SDHB-associated PGL. Computed tomography (CT) and magnetic resonance imaging (MRI) served as standards of reference. Results: Twenty-nine of 30 patients had metastatic lesions. In two patients, obvious metastatic lesions on functional imaging were missed by CT and MRI. Sensitivity according to patient/body region was 80%/65% for 123 I-MIBG and 88%/70% for [18 F]FDA-PET. False-negative results on 123 I-MIBG scintigraphy and/or [18 F]FDA-PET were not predicted by genotype or biochemical phenotype. [18 F]FDG-PET yielded a by patient/by body region sensitivity of 100%/97%. At least 90% of regions that were false negative on 123 I-MIBG scintigraphy or [18 F]FDA-PET were detected by [18 F]FDG-PET. In two patients, 111 In-pentetreotide scintigraphy detected liver lesions that were negative on other functional imaging modalities. Sensitivities were similar before and after chemotherapy or 131 I-MIBG treatment, except for a trend toward lower post- (60%/41%) versus pretreatment (80%/65%) sensitivity of 123 I-MIBG scintigraphy. Conclusion: With a sensitivity approaching 100%, [18 F]FDG-PET is the preferred functional imaging modality for staging and treatment monitoring of SDHB-related metastatic PGL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Self-citationAstuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes
Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1862 · Cited by 570
Averbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427
Ilona Linnoila, R., Keiser, H. R., Steinberg, S. M., & Lack, E. E. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90155-x · Cited by 374
Eisenhofer, G. (2001) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(01)00144-9 · Cited by 342
Self-citationBaysal, B. E., Willett-Brozick, J. E., Lawrence, E. C., Drovdlic, C. M., Savul, S. A., McLeod, D. R., Yee, H. A., Brackmann, D. E., Slattery, W. H., Myers, E. N., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.178 · Cited by 339
Schiavi, F. (2005) · JAMA · doi:10.1001/jama.294.16.2057 · Cited by 329
Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET
Shulkin, B. L., Thompson, N. W., Shapiro, B., Francis, I. R., & Sisson, J. C. (1999) · Radiology · doi:10.1148/radiology.212.1.r99jl3035 · Cited by 305
[123I]Metaiodobenzylguanidine and[111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas1
van der Harst, E., de Herder, W. W., Bruining, H. A., Bonjer, H. J., de Krijger, R. R., Lamberts, S. W. J., van de Meiracker, A. H., Boomsma, F., Stijnen, T., Krenning, E. P., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7238 · Cited by 253
Ilias, I., Yu, J., Carrasquillo, J. A., Chen, C. C., Eisenhofer, G., Whatley, M., McElroy, B., & Pacak, K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030235 · Cited by 241
Self-citationPacak, K., Eisenhofer, G., Carrasquillo, J. A., Chen, C. C., Li, S.-T., & Goldstein, D. S. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.6 · Cited by 216
Self-citationPauwels, E. K. J., Sturm, E. J. C., Bombardieri, E., Cleton, F. J., & Stokkel, M. P. M. (2000) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/pl00008465 · Cited by 169
Octreotide scintigraphy for the detection of paragangliomas.
Kwekkeboom, D. J., van Urk, H., Pauw, B. K. H., et al. (1993) · PubMed · Cited by 168
[123I]Metaiodobenzylguanidine and [111In]Octreotide Uptake in Benign and Malignant Pheochromocytomas
van der Harst, E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.685 · Cited by 131
Lynn, M. D., Shapiro, B., Sisson, J. C., et al. (1985) · Radiology · doi:10.1148/radiology.155.3.4001380 · Cited by 102
Cachin, F., Prince, H., Hogg, A., Ware, R., & Hicks, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6326 · Cited by 99
Shulkin, B. L., Koeppe, R. A., Francis, I. R., Deeb, G. M., Lloyd, R. V., & Thompson, N. W. (1993) · Radiology · doi:10.1148/radiology.186.3.8430179 · Cited by 93
Mamede, M. H., Carrasquillo, J. A., Chen, C. C., Corral, P. D., Whatley, M. A., Ilias, Ι., Ayala, A., & Pacák, K. (2005) · Nuclear Medicine Communications · doi:10.1097/01.mnm.0000189780.54658.e8 · Cited by 93
Self-citationTreatment of Malignant Pheochromocytomas With 131-I Metaiodobenzylguanidine and Chemotherapy
Sisson, J. C., Shapiro, B., Shulkin, B. L., Urba, S. G., Zempel, S., & Spaulding, S. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199908000-00008 · Cited by 87
Mann, G. N., Link, J. M., Pham, P., Pickett, C. A., Byrd, D. R., Kinahan, P. E., Krohn, K. A., & Mankoff, D. A. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.04.022 · Cited by 79
van der Horst‐Schrivers, A. N. A., Jager, P. L., Boezen, H. M., Schouten, J. P., Kema, I. P., & Links, T. P. (2006) · PubMed · Cited by 77
New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas
Ilias, Ι., Shulkin, B. L., & Pacák, K. (2005) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2005.01.007 · Cited by 65
18FDG PET in oncology: The best and the worst (Review)
Belhocine, T., Spaepen, K., Dusart, M., Castaigne, C., Muylle, K., Bourgeois, P., Bourgeois, D., Dierickx, L., & Flamen, P. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1249 · Cited by 65
A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma
Pacák, K., Goldstein, D. S., Doppman, J. L., Shulkin, B. L., Udelsman, R., & Eisenhofer, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7714 · Cited by 59
Self-citationHuynh, T., Pacák, K., Brouwers, F. M., Abu-Asab, M. S., Worrell, R., Walther, M. M., Elkahloun, A. G., Goldstein, D. S., Cleary, S., & Eisenhofer, G. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01987 · Cited by 55
Self-citationParaganglioma—All in the Family
Young, W. F., & Abboud, A. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2758 · Cited by 50
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationChen, H., Sippel, R. S., O'Dorisio, M. S., Vinik, A. I., Lloyd, R. V., & Pacak, K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb4f0 · Cited by 593
Self-citationTaïeb, D., Hicks, R. J., Hindié, E., Guillet, B. A., Avram, A., Ghedini, P., Timmers, H. J., Scott, A. T., Elojeimy, S., Rubello, D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04398-1 · Cited by 403
Self-citationBurnichon, N., Rohmer, V., Amar, L., Herman, P., Leboulleux, S., Darrouzet, V., Niccoli, P., Gaillard, D., Chabrier, G., Chabolle, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2504 · Cited by 378
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Berruti, A., Baudin, E., Gelderblom, H., Haak, H. R., Porpiglia, F., Fassnacht, M., & Pentheroudakis, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds231 · Cited by 331
Metadata
- Authors
- Timmers, H. J. L. M., Kozupa, A., Chen, C. C., Carrasquillo, J. A., Ling, A., Eisenhofer, G., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-06-01
- Volume
- 25
- Issue
- 16
- Pages
- 2262-2269
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142974837
- Cited by
- 340
- References
- 31
- FWCI
- 24.16
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.